Reasons to Retain Veeva Systems Stock in Your Portfolio for Now

Veeva Systems (VEEV) is expected to continue its growth trajectory, driven by a strong product portfolio, strategic deals, and a solid Q4 fiscal 2025 performance, with shares up 13.2% year-to-date. The company is seeing increased adoption of its Vault CRM and Clinical Development Cloud, along with momentum in its Data Cloud solutions, further bolstered by partnerships with companies like Boehringer Ingelheim and Walgreens Boots Alliance; however, rising operating costs, with general and administrative expenses up 20.6% year-over-year in Q4, remain a potential headwind.

Analysis

Veeva Systems (VEEV) demonstrates a strong growth outlook, underpinned by its robust product portfolio and strategic initiatives, as reflected in its 13.2% year-to-date share price increase, which outpaces its industry's 11.6% growth and contrasts with the S&P 500's 1.8% decrease over the same period. The company's fiscal fourth-quarter 2025 performance was solid, with both earnings and revenues exceeding consensus estimates, largely driven by its Subscription services segment. Key growth catalysts include the accelerating adoption of its next-generation Vault CRM, which added 20 new customers in the fourth quarter, and its Clinical Development Cloud, now utilized by 17 of the top 20 pharmaceutical companies. Additionally, Veeva’s Data Cloud solutions, including Compass and the new Pulse product which recently secured its first seven-figure deal, are gaining significant momentum. Strategic partnerships, such as the expanded collaboration with Boehringer Ingelheim for Vault CRM and the new alliance with Walgreens Boots Alliance for Data Cloud and Clinical Platform, are expected to further enhance market penetration. Veeva anticipates a 26.2% growth rate over the next five years and has seen a positive, albeit minor, upward revision in its fiscal 2026 earnings per share estimate to $7.30. However, a notable concern is the escalation in operating costs: general and administrative expenses rose 20.6% year-over-year in the fourth quarter of fiscal 2025, and total operating expenses increased by 9.3%, with management anticipating further growth in these expenses in fiscal 2025 due to increased headcount and employee-related costs.

Key Decisions for Investors

• Investors should carefully monitor Veeva's operating expense trajectory, specifically the growth in general and administrative (up 20.6% YoY in Q4 FY25) and sales and marketing costs, relative to revenue expansion to assess margin sustainability.
• Given the strong product adoption, particularly in Vault CRM and Data Cloud, strategic partnerships, and a projected five-year growth rate of 26.2%, current shareholders might consider retaining their positions, while prospective investors should weigh these growth drivers against the current Zacks Rank #3 (Hold) and rising operational expenditures.
• Key performance indicators to track include the pace of migration of top 20 pharmaceutical firms to Vault CRM ahead of the 2030 legacy system sunset, the magnitude of new enterprise deals for Data Cloud solutions, and the company's ability to successfully integrate AI innovations to drive efficiency and maintain its competitive edge.